Laboratorios Richmond S.A.C.I.F. (BCBA: RICH)
Argentina
· Delayed Price · Currency is ARS
1,745.00
-5.00 (-0.29%)
Nov 14, 2024, 4:58 PM BRT
RICH Income Statement
Financials in millions ARS. Fiscal year is January - December.
Millions ARS. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
Revenue | 37,546 | 39,028 | 57,518 | 32,366 | 9,330 | 5,303 | Upgrade
|
Revenue Growth (YoY) | -57.16% | -32.15% | 77.71% | 246.90% | 75.95% | 89.72% | Upgrade
|
Cost of Revenue | 11,928 | 18,718 | 30,340 | 22,765 | 4,783 | 2,728 | Upgrade
|
Gross Profit | 25,617 | 20,310 | 27,178 | 9,602 | 4,547 | 2,574 | Upgrade
|
Selling, General & Admin | 11,875 | 15,011 | 17,935 | 5,110 | 2,218 | 1,512 | Upgrade
|
Other Operating Expenses | 778.34 | - | - | - | - | - | Upgrade
|
Operating Expenses | 12,653 | 15,011 | 17,935 | 5,110 | 2,218 | 1,512 | Upgrade
|
Operating Income | 12,964 | 5,299 | 9,243 | 4,492 | 2,329 | 1,063 | Upgrade
|
Interest Expense | - | -5,308 | -4,456 | -1,451 | -506.18 | -192.4 | Upgrade
|
Interest & Investment Income | 469.81 | - | - | - | - | - | Upgrade
|
Earnings From Equity Investments | -6.5 | -3.85 | 7.33 | - | - | - | Upgrade
|
Currency Exchange Gain (Loss) | -17,906 | -25,288 | -9,159 | -1,783 | -881.81 | -784.54 | Upgrade
|
Other Non Operating Income (Expenses) | 19,684 | 14,900 | 5,828 | 61.01 | 213.93 | 156.39 | Upgrade
|
EBT Excluding Unusual Items | 15,205 | -10,401 | 1,462 | 1,319 | 1,154 | 242.24 | Upgrade
|
Impairment of Goodwill | -240.5 | -240.5 | - | - | - | - | Upgrade
|
Gain (Loss) on Sale of Investments | 6,388 | -3,282 | 1,019 | 1,436 | -11.36 | 21.63 | Upgrade
|
Gain (Loss) on Sale of Assets | - | - | 8.19 | 6.46 | 0.58 | 0.34 | Upgrade
|
Other Unusual Items | - | - | - | - | - | 22.05 | Upgrade
|
Pretax Income | 21,353 | -13,924 | 2,490 | 2,761 | 1,144 | 286.25 | Upgrade
|
Income Tax Expense | 4,217 | -2,998 | 1,993 | 1,590 | 410.18 | 115.3 | Upgrade
|
Earnings From Continuing Operations | 17,136 | -10,926 | 496.36 | 1,172 | 733.5 | 170.95 | Upgrade
|
Minority Interest in Earnings | 32.1 | 75.55 | 12.58 | -19.42 | 0.44 | -12.43 | Upgrade
|
Net Income | 17,168 | -10,851 | 508.94 | 1,152 | 733.94 | 158.52 | Upgrade
|
Net Income to Common | 17,168 | -10,851 | 508.94 | 1,152 | 733.94 | 158.52 | Upgrade
|
Net Income Growth | - | - | -55.83% | 56.98% | 362.98% | - | Upgrade
|
Shares Outstanding (Basic) | 81 | 81 | 81 | 81 | 81 | 81 | Upgrade
|
Shares Outstanding (Diluted) | 81 | 81 | 81 | 81 | 81 | 81 | Upgrade
|
Shares Change (YoY) | -0.03% | -0.04% | 0.06% | -0.00% | -0.17% | 0.23% | Upgrade
|
EPS (Basic) | 212.59 | -134.37 | 6.30 | 14.27 | 9.09 | 1.96 | Upgrade
|
EPS (Diluted) | 212.59 | -134.37 | 6.30 | 14.27 | 9.09 | 1.96 | Upgrade
|
EPS Growth | - | - | -55.85% | 56.99% | 363.78% | - | Upgrade
|
Free Cash Flow | 7,040 | -11,910 | -34,174 | -3,045 | -742.76 | -257.64 | Upgrade
|
Free Cash Flow Per Share | 87.17 | -147.48 | -423.02 | -37.71 | -9.20 | -3.19 | Upgrade
|
Dividend Per Share | - | - | - | - | 0.555 | - | Upgrade
|
Gross Margin | 68.23% | 52.04% | 47.25% | 29.67% | 48.73% | 48.55% | Upgrade
|
Operating Margin | 34.53% | 13.58% | 16.07% | 13.88% | 24.96% | 20.04% | Upgrade
|
Profit Margin | 45.73% | -27.80% | 0.88% | 3.56% | 7.87% | 2.99% | Upgrade
|
Free Cash Flow Margin | 18.75% | -30.52% | -59.41% | -9.41% | -7.96% | -4.86% | Upgrade
|
EBITDA | 12,491 | 6,441 | 11,522 | 5,165 | 2,584 | 1,249 | Upgrade
|
EBITDA Margin | 33.27% | 16.50% | 20.03% | 15.96% | 27.69% | 23.56% | Upgrade
|
D&A For EBITDA | -472.71 | 1,142 | 2,279 | 673.2 | 255.12 | 186.31 | Upgrade
|
EBIT | 12,964 | 5,299 | 9,243 | 4,492 | 2,329 | 1,063 | Upgrade
|
EBIT Margin | 34.53% | 13.58% | 16.07% | 13.88% | 24.96% | 20.04% | Upgrade
|
Effective Tax Rate | 19.75% | - | 80.06% | 57.57% | 35.87% | 40.28% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.